Allan Hansen

Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. / Rahayel, Shady; Tremblay, Christina; Vo, Andrew et al.
In: Brain, Vol. 145, No. 9, 09.2022, p. 3162-3178.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Rahayel, S, Tremblay, C, Vo, A, Zheng, Y-Q, Lehéricy, S, Arnulf, I, Vidailhet, M, Corvol, J-C, ICEBERG Study Group, Gagnon, J-F, Postuma, RB, Montplaisir, J, Lewis, S, Matar, E, Ehgoetz Martens, K, Borghammer, P, Knudsen, K, Hansen, A, Monchi, O, Misic, B & Dagher, A 2022, 'Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression', Brain, vol. 145, no. 9, pp. 3162-3178. https://doi.org/10.1093/brain/awac187

APA

Rahayel, S., Tremblay, C., Vo, A., Zheng, Y-Q., Lehéricy, S., Arnulf, I., Vidailhet, M., Corvol, J-C., ICEBERG Study Group, Gagnon, J-F., Postuma, R. B., Montplaisir, J., Lewis, S., Matar, E., Ehgoetz Martens, K., Borghammer, P., Knudsen, K., Hansen, A., Monchi, O., ... Dagher, A. (2022). Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. Brain, 145(9), 3162-3178. https://doi.org/10.1093/brain/awac187

CBE

Rahayel S, Tremblay C, Vo A, Zheng Y-Q, Lehéricy S, Arnulf I, Vidailhet M, Corvol J-C, ICEBERG Study Group, Gagnon J-F, et al. 2022. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. Brain. 145(9):3162-3178. https://doi.org/10.1093/brain/awac187

MLA

Vancouver

Rahayel S, Tremblay C, Vo A, Zheng Y-Q, Lehéricy S, Arnulf I et al. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. Brain. 2022 Sept;145(9):3162-3178. Epub 2022 May 20. doi: 10.1093/brain/awac187

Author

Rahayel, Shady ; Tremblay, Christina ; Vo, Andrew et al. / Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. In: Brain. 2022 ; Vol. 145, No. 9. pp. 3162-3178.

Bibtex

@article{fd8b4fad1ed14f06a88278f87e482580,
title = "Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression",
abstract = "Isolated REM sleep behaviour disorder (iRBD) is a synucleinopathy characterized by abnormal behaviours and vocalizations during REM sleep. Most iRBD patients develop dementia with Lewy bodies, Parkinson's disease, or multiple system atrophy over time. Patients with iRBD exhibit brain atrophy patterns that are reminiscent of those observed in overt synucleinopathies. However, the mechanisms linking brain atrophy to the underlying alpha-synuclein pathophysiology are poorly understood. Our objective was to investigate how the prion-like and regional vulnerability hypotheses of alpha-synuclein might explain brain atrophy in iRBD. Using a multicentric cohort of 182 polysomnography-confirmed iRBD patients who underwent T1-weighted MRI, we performed vertex-based cortical surface and deformation-based morphometry analyses to quantify brain atrophy in patients (67.8 years, 84% men) and 261 healthy controls (66.2 years, 75%) and investigated the morphological correlates of motor and cognitive functioning in iRBD. Next, we applied the agent-based Susceptible-Infected-Removed model (i.e., a computational model that simulates in silico the spread of pathologic alpha-synuclein based on structural connectivity and gene expression) and tested if it recreated atrophy in iRBD by statistically comparing simulated regional brain atrophy to the atrophy observed in patients. The impact of SNCA and GBA gene expression and brain connectivity was then evaluated by comparing the model fit to the one obtained in null models where either gene expression or connectivity was randomized. The results showed that iRBD patients present with cortical thinning and tissue deformation, which correlated with motor and cognitive functioning. Next, we found that the computational model recreated cortical thinning (r = 0.51, p = 0.0007) and tissue deformation (r = 0.52, p = 0.0005) in patients, and that the connectome's architecture along with SNCA and GBA gene expression contributed to shaping atrophy in iRBD. We further demonstrated that the full agent-based model performed better than network measures or gene expression alone in recreating the atrophy pattern in iRBD. In summary, atrophy in iRBD is extensive, correlates with motor and cognitive function, and can be recreated using the dynamics of agent-based modelling, structural connectivity, and gene expression. These findings support the concepts that both prion-like spread and regional susceptibility account for the atrophy observed in prodromal synucleinopathies. Therefore, the agent-based Susceptible-Infected-Removed model may be a useful tool for testing hypotheses underlying neurodegenerative diseases and new therapies aimed at slowing or stopping the spread of alpha-synuclein pathology.",
keywords = "Atrophy/pathology, Brain/pathology, Cerebral Cortical Thinning, Female, Gene Expression, Humans, Male, Neurodegenerative Diseases/pathology, Prions/metabolism, REM Sleep Behavior Disorder/metabolism, Synucleinopathies/diagnostic imaging, alpha-Synuclein/genetics",
author = "Shady Rahayel and Christina Tremblay and Andrew Vo and Ying-Qiu Zheng and St{\'e}phane Leh{\'e}ricy and Isabelle Arnulf and Marie Vidailhet and Jean-Christophe Corvol and {ICEBERG Study Group} and Jean-Fran{\c c}ois Gagnon and Postuma, {Ronald B} and Jacques Montplaisir and Simon Lewis and Elie Matar and {Ehgoetz Martens}, Kaylena and Per Borghammer and Karoline Knudsen and Allan Hansen and Oury Monchi and Bratislav Misic and Alain Dagher",
year = "2022",
month = sep,
doi = "10.1093/brain/awac187",
language = "English",
volume = "145",
pages = "3162--3178",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression

AU - Rahayel, Shady

AU - Tremblay, Christina

AU - Vo, Andrew

AU - Zheng, Ying-Qiu

AU - Lehéricy, Stéphane

AU - Arnulf, Isabelle

AU - Vidailhet, Marie

AU - Corvol, Jean-Christophe

AU - ICEBERG Study Group

AU - Gagnon, Jean-François

AU - Postuma, Ronald B

AU - Montplaisir, Jacques

AU - Lewis, Simon

AU - Matar, Elie

AU - Ehgoetz Martens, Kaylena

AU - Borghammer, Per

AU - Knudsen, Karoline

AU - Hansen, Allan

AU - Monchi, Oury

AU - Misic, Bratislav

AU - Dagher, Alain

PY - 2022/9

Y1 - 2022/9

N2 - Isolated REM sleep behaviour disorder (iRBD) is a synucleinopathy characterized by abnormal behaviours and vocalizations during REM sleep. Most iRBD patients develop dementia with Lewy bodies, Parkinson's disease, or multiple system atrophy over time. Patients with iRBD exhibit brain atrophy patterns that are reminiscent of those observed in overt synucleinopathies. However, the mechanisms linking brain atrophy to the underlying alpha-synuclein pathophysiology are poorly understood. Our objective was to investigate how the prion-like and regional vulnerability hypotheses of alpha-synuclein might explain brain atrophy in iRBD. Using a multicentric cohort of 182 polysomnography-confirmed iRBD patients who underwent T1-weighted MRI, we performed vertex-based cortical surface and deformation-based morphometry analyses to quantify brain atrophy in patients (67.8 years, 84% men) and 261 healthy controls (66.2 years, 75%) and investigated the morphological correlates of motor and cognitive functioning in iRBD. Next, we applied the agent-based Susceptible-Infected-Removed model (i.e., a computational model that simulates in silico the spread of pathologic alpha-synuclein based on structural connectivity and gene expression) and tested if it recreated atrophy in iRBD by statistically comparing simulated regional brain atrophy to the atrophy observed in patients. The impact of SNCA and GBA gene expression and brain connectivity was then evaluated by comparing the model fit to the one obtained in null models where either gene expression or connectivity was randomized. The results showed that iRBD patients present with cortical thinning and tissue deformation, which correlated with motor and cognitive functioning. Next, we found that the computational model recreated cortical thinning (r = 0.51, p = 0.0007) and tissue deformation (r = 0.52, p = 0.0005) in patients, and that the connectome's architecture along with SNCA and GBA gene expression contributed to shaping atrophy in iRBD. We further demonstrated that the full agent-based model performed better than network measures or gene expression alone in recreating the atrophy pattern in iRBD. In summary, atrophy in iRBD is extensive, correlates with motor and cognitive function, and can be recreated using the dynamics of agent-based modelling, structural connectivity, and gene expression. These findings support the concepts that both prion-like spread and regional susceptibility account for the atrophy observed in prodromal synucleinopathies. Therefore, the agent-based Susceptible-Infected-Removed model may be a useful tool for testing hypotheses underlying neurodegenerative diseases and new therapies aimed at slowing or stopping the spread of alpha-synuclein pathology.

AB - Isolated REM sleep behaviour disorder (iRBD) is a synucleinopathy characterized by abnormal behaviours and vocalizations during REM sleep. Most iRBD patients develop dementia with Lewy bodies, Parkinson's disease, or multiple system atrophy over time. Patients with iRBD exhibit brain atrophy patterns that are reminiscent of those observed in overt synucleinopathies. However, the mechanisms linking brain atrophy to the underlying alpha-synuclein pathophysiology are poorly understood. Our objective was to investigate how the prion-like and regional vulnerability hypotheses of alpha-synuclein might explain brain atrophy in iRBD. Using a multicentric cohort of 182 polysomnography-confirmed iRBD patients who underwent T1-weighted MRI, we performed vertex-based cortical surface and deformation-based morphometry analyses to quantify brain atrophy in patients (67.8 years, 84% men) and 261 healthy controls (66.2 years, 75%) and investigated the morphological correlates of motor and cognitive functioning in iRBD. Next, we applied the agent-based Susceptible-Infected-Removed model (i.e., a computational model that simulates in silico the spread of pathologic alpha-synuclein based on structural connectivity and gene expression) and tested if it recreated atrophy in iRBD by statistically comparing simulated regional brain atrophy to the atrophy observed in patients. The impact of SNCA and GBA gene expression and brain connectivity was then evaluated by comparing the model fit to the one obtained in null models where either gene expression or connectivity was randomized. The results showed that iRBD patients present with cortical thinning and tissue deformation, which correlated with motor and cognitive functioning. Next, we found that the computational model recreated cortical thinning (r = 0.51, p = 0.0007) and tissue deformation (r = 0.52, p = 0.0005) in patients, and that the connectome's architecture along with SNCA and GBA gene expression contributed to shaping atrophy in iRBD. We further demonstrated that the full agent-based model performed better than network measures or gene expression alone in recreating the atrophy pattern in iRBD. In summary, atrophy in iRBD is extensive, correlates with motor and cognitive function, and can be recreated using the dynamics of agent-based modelling, structural connectivity, and gene expression. These findings support the concepts that both prion-like spread and regional susceptibility account for the atrophy observed in prodromal synucleinopathies. Therefore, the agent-based Susceptible-Infected-Removed model may be a useful tool for testing hypotheses underlying neurodegenerative diseases and new therapies aimed at slowing or stopping the spread of alpha-synuclein pathology.

KW - Atrophy/pathology

KW - Brain/pathology

KW - Cerebral Cortical Thinning

KW - Female

KW - Gene Expression

KW - Humans

KW - Male

KW - Neurodegenerative Diseases/pathology

KW - Prions/metabolism

KW - REM Sleep Behavior Disorder/metabolism

KW - Synucleinopathies/diagnostic imaging

KW - alpha-Synuclein/genetics

U2 - 10.1093/brain/awac187

DO - 10.1093/brain/awac187

M3 - Journal article

C2 - 35594873

VL - 145

SP - 3162

EP - 3178

JO - Brain

JF - Brain

SN - 0006-8950

IS - 9

ER -